The current diagnostic pathway for breast cancer is cumbersome as very often two and sometimes three different imaging modalities need to be used to come to a diagnosis. Pathologic assessment of resected tissue specimens is seen as the golden standard and is performed on top of imaging to confirm the diagnosis. A non-invasive imaging modality with a high sensitivity and specificity for all breast lesion types, which can be used as a stand-alone technique and replaces the currently used modalities, can be considered as the holy grail in breast cancer screening and diagnosis. The introduction of such a modality can drastically reduce healthcare costs and also lower the burden to the patient.
|Qualification||Doctor of Philosophy|
|Award date||10 Dec 2021|
|Place of Publication||Enschede|
|Publication status||Published - 10 Dec 2021|